Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
IDH2 mutation
i
Other names:
IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3418
Related biomarkers:
Expression
Mutation
Others
‹
IDH2 mutation + Chr del(1p) + Chr del(19q) (9)
IDH2 mutation + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)
IDH2 mutation + NTRK1 fusion (2)
IDH2 mutation + NTRK2 fusion (2)
IDH2 mutation + NTRK3 fusion (2)
MYC overexpression + IDH2 mutation (2)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)
IDH wild-type + FGFR3 S249C + TP53 V73fs (1)
IDH2 mutation + ALK fusion (1)
IDH2 mutation + MGMT promoter methylation (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + TMB-L (1)
PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)
PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)
IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)
IDH2 mutation + Chr del(1p) + Chr del(19q) (9)
IDH2 mutation + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion (2)
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion (2)
IDH2 mutation + NTRK1 fusion (2)
IDH2 mutation + NTRK2 fusion (2)
IDH2 mutation + NTRK3 fusion (2)
MYC overexpression + IDH2 mutation (2)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion (1)
IDH wild-type + FGFR3 S249C + TP53 V73fs (1)
IDH2 mutation + ALK fusion (1)
IDH2 mutation + MGMT promoter methylation (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + TMB-L (1)
PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)
PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17) (1)
IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)
›
Related tests:
Oncomine™ Dx Target Test (11)
Oncomine™ Dx Target Test (11)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
IDH2 mutation
Oligodendroglioma
IDH2 mutation
Oligodendroglioma
vorasidenib
Sensitive: A1 - Approval
vorasidenib
Sensitive
:
A1
vorasidenib
Sensitive: A1 - Approval
vorasidenib
Sensitive
:
A1
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
vorasidenib
Sensitive: A1 - Approval
vorasidenib
Sensitive
:
A1
vorasidenib
Sensitive: A1 - Approval
vorasidenib
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
carmustine
Sensitive: A2 - Guideline
carmustine
Sensitive
:
A2
carmustine
Sensitive: A2 - Guideline
carmustine
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
lomustine
Sensitive: A2 - Guideline
lomustine
Sensitive
:
A2
lomustine
Sensitive: A2 - Guideline
lomustine
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
IDH2 mutation
Astrocytoma
IDH2 mutation
Astrocytoma
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.